Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma

Cancer

Volumn 77, Issue 7, 1996, Pages 1284-1291

  Schleusener, Jeffrey T ^a   Tazelaar, Henry D ^a   Jung, Sin Ho ^a   Cha, Stephen S ^a   Cera, Peter J ^b   Myers, Jeffrey L ^a   Creagan, Edward T ^a   Goldberg, Richard M ^a   Marschke Jr , Robert F ^c  

^a MAYO CLINIC   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

chromogranin; Leu 7; neuroendocrine; Nonsmall cell lung carcinoma; small cell lung carcinoma; synaptophysin

Indexed keywords

CHROMOGRANIN A; CISPLATIN; ETOPOSIDE; HYDRAZINE; KERATIN; SYNAPTOPHYSIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DIAGNOSIS; ELECTRON MICROSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CISPLATIN; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; HYDRAZINES; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; PROGNOSIS; STAINING AND LABELING;

EID: 0029930259     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1284::AID-CNCR9>3.0.CO;2-I     Document Type: Article

References (31)

1. Parker SL, Tong T, Boldens, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996:5-27.
2. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:2255-2335.
3. The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol 1982;77:123-36.
4. Guinee Jr DG, Fishback NF, Koss MN, Abbondanzo SL, Travis WD, The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994;102: 406-14.
5. Mool WJ, Dingemans KP, Wagenaar SjSc, Hart AAM, Wagenvoort CA. Ultrastructural heterogeneity of lung carcinomas: representativity of samples for electron microscopy in tumor classification. Hum Pathol 1990;21:1227-34.
6. Hirsch FR, Skov BG. Neuroendocrine characteristics in bronchogenic adenocarcinoma and its clinical relevance. Lung Cancer 1993;9:89-96.
7. Hirsch FR. The clinical implication of neuroendocrine markers in non-small cell lung cancer. Lung Cancer 1994;11:201-2.
8. Graziano SL, Mazid R, Newman N, Tatum A, Oler A, Mortimer JA, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J Clin Oncol 1989;7:1398-406.
9. Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, Fernandez-Vasalo G, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993;10:209-19.
10. Skov BG, Sorensen JB, Hirsch FR, Larsson LI, Hansen HH. Prognostic impact of histologic demonstration of Chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 1991;2:355-60.
11. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer: the LCSG experience. Chest 1994;106:367S-71S.
12. Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen NM. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer 1991;64:333-8.
13. Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ, et al. Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989;7:1614-20.
14. Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, et al. The prognostic significance of neuroendocrine markers and carcinoembryoinc antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res 1994;54:2908-13.
15. Ruckdeschel J, Linnoila RI, Mulshine JL, Kim K, Piantadosi S, Aisner S. et al. The impact of neuroendocrine and epithelial differentiation on recurrence and survival in patients with lung cancer [abstract]. Proc Am Soc Clin Oncol 1991;10:248.
16. Kibbelaar RE, Moolenaar KEC, Michalides RJAM, Van Bodegom PC, Vanderschueren RGJRA, Wagenaar SS, et al. Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer 1991;27:431-5.
17. Loprinzi CL, Goldberg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994;12:1126-9.
18. Hsu SM, Raine L, Fanger H. A comparative study of the PAP method and avidin-biotin-complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981;75:734-8.
19. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-53.
20. Linnoila RI, Mulshine JL, Steinberg SM, Funa K, Matthews MJ, Cotelingam JD, et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol 1988;90:641-52.
21. Neal MH, Kosinski R, Cohen P, Orenstein JM. Atypical endocrine tumors of the lung: a histologic, ultrastructural, and clinical study of 19 cases. Hum Pathol 1986;17:1264-77.
22. Wick MR, Berg LC, Hertz MI. Large cell carcinoma of the lung with neuroendocrine differentiation. A comparison with large cell "undifferentiated" pulmonary tumors. Am J Clin Pathol 1992;97:796-805.
23. Warren WH, Faber LP, Gould VE. Neuroendocrine neoplasms of the lung. A clinicopathologic update. J Thorac Cardiovasc Surg 1989;98:321-32.
24. Bunn PA, Linnoila I, Minna JD, Carney D, Gazdar AF. Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells. Blood 1985;65: 764-8.
25. Sato Y, Watanabe S, Kodama T, Goto M, Shimosato Y. Stainability of lung cancer cells with Leu-7 and OKT-9 monoclonal antibodies. Jpn J Clin Oncol 1985;15:537-44.
26. Gould VE, Wiedenmann B, Lee I, Schwechheimer K, Dockhorn-Dworniczak B, Radosevich JA, et al. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol 1987;126:243-57.
27. Haimoto H, Takahashi Y, Koshikawa T, Nagura H, Kato K. Immunohistochemical localization of γ-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 1985;52:257-63.
28. Vinores SA, Bonnin JM, Rubinstein LJ, Marangos PJ. Immunohistochemical demonstration of neuron-specific enolase in neoplasms of the CNS and other tissues. Arch Pathol Lab Med 1984;108:536-40.
29. Dranoff G, Bigner DD. A word of caution in the use of neuron-specific enolase expression in tumor diagnosis. Arch Pathol Lab Med 1984;108:535.
30. Thomas P, Battifora H, Manderino GL, Patrick J. A monoclonal antibody against neuron-specific enolase. Immunohistochemical comparison with a polyclonal antiserum. Am J Clin Pathol 1987;88:146-52.
31. Loy TS, Darkow GVD, Quesenberry JT. Immunostaining in the diagnosis of pulmonary neuroendocrine carcinomas. An immunohistochemical study with ultrastructural correlations. Am J Surg Pathol 1995;19:173-82.